Cardiovascular Effects of Home Intensive Hemodialysis

Advances in Chronic Kidney Disease

Volumn 16, Issue 3, 2009, Pages 173-178

  Chan, Christopher T ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Cardiovascular outcomes; Frequent hemodialysis; Nocturnal home hemodialysis; Short daily dialysis

Indexed keywords

CALCIUM PHOSPHATE;

ANEMIA; ARTICLE; BLOOD PRESSURE REGULATION; CALCIUM METABOLISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; GEOMETRY; HOME DIALYSIS; KIDNEY FAILURE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; UREMIA;

CARDIOVASCULAR DISEASES; HEMODIALYSIS, HOME; HUMANS; KIDNEY FAILURE, CHRONIC; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 64849091031     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2009.02.003     Document Type: Article

References (39)

1. Collins A.J. Cardiovascular mortality in end-stage renal disease. Am J Med Sci 325 (2003) 163-167
2. DePalma J.R., Pecker E.A., Gordon A., et al. A new compact automatic home hemodialysis system. Trans Am Soc Artif Intern Organs 14 (1968) 152-159
3. Uldall R., Ouwendyk M., Francoeur R., et al. Slow nocturnal home hemodialysis at the Wellesley Hospital. Adv Ren Replace Ther 3 (1996) 133-136
4. Kraus M., Burkart J., Hegeman R., et al. A comparison of center-based vs. home-based daily hemodialysis for patients with end-stage renal disease. Hemodial Int 11 (2007) 468-477
5. Lindner A., Charra B., Sherrard D.J., et al. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 290 (1974) 697-701
6. London G.M. Cardiovascular disease in chronic renal failure: Pathophysiologic aspects. Semin Dial 16 (2003) 85-94
7. Zoccali C., Mallamaci F., and Tripepi G. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int Suppl (2003) 105-110
8. Hruska K.A., Mathew S., Lund R., et al. Hyperphosphatemia of chronic kidney disease. Kidney Int 74 (2008) 148-157
9. Amann K., Ritz E., Wiest G., et al. A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 4 (1994) 1814-1819
10. Foley R.N. Clinical epidemiology of cardiac disease in dialysis patients: Left ventricular hypertrophy, ischemic heart disease, and cardiac failure. Semin Dial 16 (2003) 111-117
11. Szmitko P.E., Fedak P.W., Weisel R.D., et al. Endothelial progenitor cells: New hope for a broken heart. Circulation 107 (2003) 3093-3100
12. Tongers J., and Losordo D.W. Frontiers in nephrology: The evolving therapeutic applications of endothelial progenitor cells. J Am Soc Nephrol 18 (2007) 2843-2852
13. London G.M. Vascular disease and atherosclerosis in uremia. Blood Purification 19 (2001) 139-142
14. Woods J.D., Port F.K., Orzol S., et al. Clinical and biochemical correlates of starting "daily" hemodialysis. Kidney Int 55 (1999) 2467-2476
15. Fagugli R.M., Reboldi G., Quintaliani G., et al. Short daily hemodialysis: Blood pressure control and left ventricular mass reduction in hypertensive hemodialysis patients. Am J Kidney Dis 38 (2001) 371-376
16. Chan C.T., Floras J.S., Miller J.A., et al. Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int 61 (2002) 2235-2239
17. Nesrallah G., Suri R., Moist L., et al. Volume control and blood pressure management in patients undergoing quotidian hemodialysis. Am J Kidney Dis 42 (2003) 13-17
18. Chan C.T., Harvey P.J., Picton P., et al. Short-term blood pressure, noradrenergic, and vascular effects of nocturnal home hemodialysis. Hypertension 42 (2003) 925-931
19. Foley R.N., Parfrey P.S., Harnett J.D., et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney International 47 (1995) 186-192
20. Culleton B.F., Walsh M., Klarenbach S.W., et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: A randomized controlled trial. JAMA 298 (2007) 1291-1299
21. Suri R.S., Garg A.X., Chertow G.M., et al. Frequent Hemodialysis Network (FHN) randomized trials: Study design. Kidney Int 71 (2007) 349-359
22. Raggi P., and Kleerekoper M. Contribution of bone and mineral abnormalities to cardiovascular disease in patients with chronic kidney disease. Clin J Am Soc Nephrol 3 (2008) 836-843
23. Chan C.T., Jain V., Picton P., et al. Nocturnal hemodialysis increases arterial baroreflex sensitivity and compliance and normalizes blood pressure of hypertensive patients with end-stage renal disease. Kidney Int 68 (2005) 338-344
24. Chan C.T., Shen X.S., Picton P., et al. Nocturnal home hemodialysis improves baroreflex effectiveness index of end-stage renal disease patients. J Hypertens 26 (2008) 1795-1800
25. Suki W.N. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: Results of a randomized clinical trial. J Ren Nutr 18 (2008) 91-98
26. Manns B., Klarenbach S., Lee H., et al. Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant 22 (2007) 2867-2878
27. Tonelli M., Sacks F., Pfeffer M., et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 112 (2005) 2627-2633
28. Spalding E.M., Chamney P.W., and Farrington K. Phosphate kinetics during hemodialysis: Evidence for biphasic regulation. Kidney Int 61 (2002) 655-667
29. Kim S.J., Goldstein M., Szabo T., et al. Resolution of massive uremic tumoral calcinosis with daily nocturnal home hemodialysis. Am J Kidney Dis 41 (2003) E12
30. Yuen D., Pierratos A., Richardson R.M., et al. The natural history of coronary calcification progression in a cohort of nocturnal haemodialysis patients. Nephrol Dial Transplant 21 (2006) 1407-1412
31. Fishbane S., and Besarab A. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol 2 (2007) 1274-1282
32. Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (1998) 584-590
33. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006) 2085-2098
34. Drueke T.B., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (2006) 2071-2084
35. Ting G.O., Kjellstrand C., Freitas T., et al. Long-term study of high-comorbidity ESRD patients converted from conventional to short daily hemodialysis. Am J Kidney Dis 42 (2003) 1020-1035
36. Schwartz D.I., Pierratos A., Richardson R.M., et al. Impact of nocturnal home hemodialysis on anemia management in patients with end-stage renal disease. Clin Nephrol 63 (2005) 202-208
37. Chan C.T., Li S.H., and Verma S. Nocturnal hemodialysis is associated with restoration of impaired endothelial progenitor cell biology in end-stage renal disease. Am J Physiol Renal Physiol 289 (2005) F679-684
38. Chan C.T., and Gold W.L. Intramedullary abscess of the spinal cord in the antibiotic era: Clinical features, microbial etiologies, trends in pathogenesis, and outcomes. Clin Infect Dis 27 (1998) 619-626
39. Ayus J.C., Mizani M.R., Achinger S.G., et al. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: A prospective, controlled study. J Am Soc Nephrol 16 (2005) 2778-2788